-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

Benzinga·08/31/2026 17:45:35
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.